单克隆抗体治疗AL淀粉样变性:同时靶向浆细胞克隆与淀粉样沉积
本文综述单克隆抗体在免疫球蛋白轻链(AL)淀粉样变性治疗中的作用,指出当前治疗仅针对克隆性浆细胞,而快速阻止并可能逆转器官损伤至关重要。单克隆抗体既可靶向恶性浆细胞(达雷妥尤单抗、伊沙妥昔单抗、埃罗妥珠单抗),也可靶向清除器官淀粉样沉积(NEOD001、CAEL-101、dezamizumab)。达雷妥尤单抗单药在复发AL淀粉样变性中疗效极佳,超过其在多发性骨髓瘤中的结果;单克隆抗体具有高选择性和低毒性优势,同时靶向浆细胞克隆和淀粉样沉积有望革命性改善AL淀粉样变性预后。
要点
- AL淀粉样变性治疗需同时针对浆细胞克隆和器官淀粉样沉积。
- 达雷妥尤单抗单药在复发AL淀粉样变性中疗效极佳。
- 单克隆抗体具有高选择性和低毒性优势。
核心结论
- 同时靶向浆细胞克隆和淀粉样沉积有望革命性改善AL淀粉样变性预后。
- 单克隆抗体具有高选择性和低毒性,可能成为该领域的游戏规则改变者。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- 达雷妥尤单抗单药在复发AL淀粉样变性中疗效极佳,超过其在多发性骨髓瘤中的结果。
- 靶向浆细胞的单克隆抗体包括达雷妥尤单抗、伊沙妥昔单抗和埃罗妥珠单抗。
- 靶向清除淀粉样沉积的单克隆抗体包括NEOD001、CAEL-101和dezamizumab。
临床怎么用
- 单克隆抗体可用于靶向恶性浆细胞或促进器官淀粉样沉积清除。
- 达雷妥尤单抗单药可考虑用于复发AL淀粉样变性。
局限性
- 摘要未报告综述的检索范围及纳入研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunoglobulin light-chain amyloidosis (AL amyloidosis) is a rare disease in which a small plasma cell clone produces toxic misfolded proteins that deposit in organs and impair their function. Currently, the only available treatment approach is the elimination of clonal plasma cells. However, a rapid strike that halts and possibly reverses organ damage is crucial. The development of agents that facilitate the clearance of pathological fibrillar deposits, therefore reducing the frailty of patients, is the needed supplement to plasma cell-directed therapy. Monoclonal antibodies provide therapy against malignant plasma cells (daratumumab, isatuximab, elotuzumab) but they are also able to target and eliminate the amyloid from organs (NEOD001, CAEL-101, dezamizumab). From the plasma cell-directed group, daratumumab in monotherapy has proved to be extremely efficient in relapsed AL amyloidosis, exceeding its results in multiple myeloma. Compared to other agents, monoclonal antibodies possess the advantage of high selectivity and low toxicity and could potentially become future game-changers in this field. Co-targetting of the plasma cell clone and amyloid deposits shall together be translated in the revolutionary improved outcome of potentially curable AL amyloidosis.
引用
- Popkova T, Hajek R, Jelinek T, et al. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits. Br J Haematol. 2020. PMID: 32072615. doi:10.1111/bjh.16436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。